Virulence: Likely Increased.
Antigenicity: B.1.617.2 variant is resistant to therapeutic monoclonal antibodies, natural infection’s or vaccine-induced antibodies.
Spread: Originally was discovered in India and has now spread to more than 60 countries. Variant is dominant in India & UK now (and many other Asian countries where sequence data is not widely available), but prevalence also growing fast in US, as well as many European countries.
Global Positive Samples Sequenced: 8,599,460
B.1.617.2 Sequenced: 151,284 (169 Countries/56 US States)
% of Global Samples Sequenced: 1.76%
Most common countries for B.1.617.2 Lineage: United States of America 27.0%, India 18.0%, United Kingdom 15.0%, Germany 5.0%, Turkey 4.0% (Predominantly India lineage with several spike mutations, pango-designation issue #49).
Summary of B.1.617.2 data
Global Samples Sequencing Data
Updated February 2022